Accord Healthcare
Accord Healthcare is a young and dynamic pharmaceutical company, involved in the development, manufacturing and distribution of pharmaceutical products to more than 70 countries globally.
DRUG
REACTION
REPORT
GROWTH’S IN OUR NATURE
Accord Healthcare is one of the fastest growing generic pharmaceutical companies in Ireland and the UK.
Acquiring Actavis Ireland and the UK in 2017 facilitates Accord’s ambition of becoming a top 5 pan-EMEA generics company by 2020 and a leading player in the industry at European level.
TRULY MULTINATIONAL
Accord has one of the most extensive sales, marketing and distribution networks in Europe. Headquartered from UK, Accord now supplies products in close to 65 EMENA markets.
A COMPLETE APPROACH
Accord’s vision is to be involved in all aspects of bringing pharmaceuticals to patients. Our activities today encompass the entire pharmaceutical value chain and so create a truly integrated offering.
EUROPEAN FOCUS
Accord currently has a portfolio comprising nearly 7000 product approvals in Europe. We operate a pan European commercial footprint with direct presence in all major EU markets.
News
Accord Healthcare Wins Company of the Year & Biosimilar Initiative of the Year
We are delighted to announce that Accord Healthcare was the most recognised company at the Global Generics & Biosimilar Awards 2018, having won awards for: Company of the Year and Biosimilar Initiative of the Year. Intas & Accord Healthcare also picked up the award for Company of the Yea
Accord Healthcare’s Pelgraz® (pegfilgrastim) Given Positive Opinion by CHMP
Following marketing authorisation grant, Pelgraz, a pegylated G-CSF biosimilar, would be the latest addition to Accord Healthcare’s established portfolio of over 30 oncology treatments across Europe.
